Kim YH, Her AY, Jeong MH, et al. - Among patients with ST-segment elevation myocardial infarction (STEMI; n = 11,706) who had undergone successful percutaneous coronary intervention (PCI) with drug-eluting stents (DES), researchers compared statin with angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) therapy, focusing on 2-year clinical outcomes. Two groups were formed: the ACEI group (statin + ACEI, n = 8,705) and the ARB group (statin + ARB, n = 3,001). The occurrence of major adverse cardiac events (MACE) was the primary endpoint. Using propensity score matching (PSM), two PSM groups (2,729 pairs, n = 5458, C-statistic = 0.675) were created. The two groups had similar cumulative incidences of MACE, recurrent MI, and any coronary revascularization. A 2-year follow-up was performed. According to findings, the combination of statin with ACEI vs statin with ARB may be a favorable treatment strategy as far as reduction in mortality rates is concerned in STEMI patients following successful PCI with DES.